Application of molecular technologies for phosphoproteomic analysis of clinical samples. - Wikidata - wikimedia - TriplyDB

Application of molecular technologies for phosphoproteomic analysis of clinical samples.

Application of molecular technologies for phosphoproteomic analysis of clinical samples.

http://www.wikidata.org/entity/Q38194417

about

The Landscape of Pancreatic Cancer Therapeutic Resistance Mechanisms Emerging proteomic technologies for elucidating context-dependent cellular signaling events: A big challenge of tiny proportions Reverse Phase Protein Arrays-Quantitative Assessment of Multiple Biomarkers in Biopsies for Clinical Use Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research: a workshop report: the RPPA (Reverse Phase Protein Array) society.Whole proteome analysis of mouse lymph nodes in cutaneous anthrax Integrating phosphoproteomics in systems biology.Impact of upfront cellular enrichment by laser capture microdissection on protein and phosphoprotein drug target signaling activation measurements in human lung cancer: Implications for personalized medicine.Reverse-Phase Microarray Analysis Reveals Novel Targets in Lymph Nodes of Bacillus anthracis Spore-Challenged Mice.Recent progress in protein profiling of clinical tissues for next-generation molecular diagnostics.A pilot study exploring the molecular architecture of the tumor microenvironment in human prostate cancer using laser capture microdissection and reverse phase protein microarray.Rapid, Multiplexed Phosphoprotein Profiling Using Silicon Photonic Sensor Arrays.Toward a systems-level view of dynamic phosphorylation networks Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3.Approaches to identify kinase dependencies in cancer signalling networks.Advancing translational research with next-generation protein microarrays.Reverse Phase Protein Microarrays.Integrated Strategies to Gain a Systems-Level View of Dynamic Signaling Networks.C-Met/miR-130b axis as novel mechanism and biomarker for castration resistance state acquisition.Impact of phosphoproteomics in the translation of kinase-targeted therapies.Harnessing the power of proteomics for identification of oncogenic, druggable signalling pathways in cancer.Signaling pathway profiling using reverse-phase protein array and its clinical applications.Chemical Proteomic Approaches Targeting Cancer Stem Cells: A Review of Current Literature.Reverse phase protein array (RPPA) combined with computational analysis to unravel relevant prognostic factors in non- small cell lung cancer (NSCLC): a pilot study.Drug repurposing for the treatment of glioblastoma multiforme.Persistent CD49d engagement in circulating CLL cells: a role for blood-borne ligands?

P2860

Q26765247-BDE3638C-44C7-4C4F-A5BF-8EF668BBCD72 Q28081956-0630552C-7A48-4D2C-BE49-AB4D98AC2A37 Q28083256-FB6C7945-4D45-489D-823F-19FDB4F13FB8 Q33850616-A5B4B2E9-BB9B-41E0-BF4E-4355AECCCD7B Q34374409-245D7DC0-613E-46C1-A74E-48C7ACABBD8C Q34377093-B4EB83DD-C780-4256-AA4B-794E627367EB Q35560129-F5803484-2D67-4F73-B952-6A08D93B06A6 Q35668869-BA6B440E-628C-4CE9-B96E-D8D724EAFA1A Q35714211-62E0A025-B1A7-4D19-8CC4-B9778B3CCA24 Q36186223-49D8AE8B-A1FF-4043-9E47-D45161927422 Q36227052-054B7E75-2C29-4776-BB2E-EA96793D8A58 Q38245231-02390C07-F238-4C29-A49E-D6853AF859C6 Q38623361-638CF6DE-3849-4DBA-B9B4-B1C03BE91BDF Q38660465-CA843BBA-1A73-44D4-81E4-1D9F02DFF655 Q38691479-9588E819-9F3D-4510-99A8-FA03CC99E9C3 Q38787411-3C56CE51-4F24-4827-8BC9-B1C2B8F543E0 Q38881491-D50BCCB2-11EA-4605-99E9-A4D7B7A0F101 Q38964120-C51F6AFD-29D9-4747-B344-CCD2F6BE3AD6 Q38989188-E2B9898C-D12E-4D3E-B751-FB37902E368F Q39175714-6D507B0E-9C3C-4ACE-9DAB-6C931FBDF121 Q39377837-7FC79A09-0975-49E7-9CC9-144D806406B7 Q41664062-23A5E981-1843-4875-B70A-2BB20C8EEAA1 Q44239255-62787B32-C295-4A79-8578-0C3411338837 Q47948290-0B018ABF-EBED-4F76-9FDA-A60D9634A3ED Q52930409-848B3B4E-D2C5-4CFC-ADB3-4CC4095F6A31

P2860

Application of molecular technologies for phosphoproteomic analysis of clinical samples.

http://www.wikidata.org/entity/Q38194417

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Application of molecular technologies for phosphoproteomic analysis of clinical samples.

@en

type

label

Application of molecular technologies for phosphoproteomic analysis of clinical samples.

@en

prefLabel

Application of molecular technologies for phosphoproteomic analysis of clinical samples.

@en

P1433

Q38194417-3CC82CD7-608D-4775-9846-EBB080380D9A

P1476

Q38194417-8EBF2590-C817-4574-81B9-D94AD747C17F

P2093

Q38194417-268BEE49-1DD5-4F53-A955-EBFB57542517

Q38194417-53223BD5-D18B-4077-9577-E048D5ED2E8B

Q38194417-B4B94111-87E8-49B9-960E-F3D65A8DA0CE

Q38194417-C9EF24A6-D5A7-45FD-B5F0-D0EC1FC04FB4

P2860

Q38194417-09488F73-002C-49CD-A374-A01A5A96EC9D

Q38194417-0AD52795-EDD3-4F69-8DD5-9EA264181E3E

Q38194417-0BFD87AA-E50C-466C-A2B1-6E15E665EA79

Q38194417-110B859D-60C8-435B-945F-92A589C68D2B

Q38194417-12251D45-520C-4FCF-A65A-6D8FE292AD64

Q38194417-123D60D9-CB3D-4796-9BFC-2EA9228F4217

Q38194417-26DA1CEC-AB5F-4088-A927-94B6C7B9F3C9

Q38194417-26EAB948-25BB-476D-92BA-5299499CFAEB

Q38194417-2926C42B-22B7-4608-B555-F2D4BC8DEB2A

Q38194417-2D4A930A-8D9B-4282-BE4F-BEE2E78B4B92

P2888

Q38194417-73E6D30D-D955-45B6-9EE3-6D8CFB6E81B0

P304

Q38194417-AAD38254-4EB0-4336-A980-BA8A4AEEFC6B

P31

Q38194417-7B046CB5-E8F8-42FF-BC23-E6AF09D54145

P356

Q38194417-97FCBE21-874D-486A-A7F5-2646A8F11C78

P407

Q38194417-B42298EF-AEC9-4804-8A63-45151622C40C

P433

Q38194417-A1EA3EA9-F0EE-489B-95B9-4B3EB97569C3

P478

Q38194417-293A92AB-99DD-435C-8536-326EC5F428D1

P577

Q38194417-9F7E89A4-16C7-40A8-A3CD-AB3B5D66953E

P6179

Q38194417-485A6D59-0AAC-4DE8-B6B9-309F8C8385DD

P698

Q38194417-36E4A7A8-E63D-4F4F-9484-EA03F64679B7

P356

P1433

P1476

Application of molecular technologies for phosphoproteomic analysis of clinical samples.

@en

P2093

E Petricoin

http://www.w3.org/2001/XMLSchema#string

J Wulfkuhle

http://www.w3.org/2001/XMLSchema#string

L Liotta

http://www.w3.org/2001/XMLSchema#string

M Pierobon

http://www.w3.org/2001/XMLSchema#string

P2860

ELISA and multiplex technologies for cytokine measurement in inflammation and aging research

Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer

First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.

I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy

Genetic alterations during colorectal-tumor development

Reverse phase protein microarrays advance to use in clinical trials

Phosphoprotein stability in clinical tissue and its relevance for reverse phase protein microarray technology.

Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front.

Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy.

Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type

P2888

P304

805-814

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/ONC.2014.16

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P577

2014-03-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1029708666

http://www.w3.org/2001/XMLSchema#string

P698

24608425

http://www.w3.org/2001/XMLSchema#string